← Back to list
MA08.045p, Tocilizumab and Related Biosimilars for Intravenous Infusion and Subcutaneous Injection
Act
by Apr 1, 2026
Effective date
Apr 1, 2026
Identified
Jun 19, 2026
Summary
Independence Blue Cross Medicare Advantage updated policy MA08.045p to MA08.045r, adding three new HCPCS codes (M0233, M0234, Q0238) for tocilizumab-aazg biosimilar COVID-19 treatment in hospitalized patients. The policy clarifies preferred versus nonpreferred tocilizumab products, establishes coverage criteria for multiple indications including rheumatoid arthritis and Castleman disease, and specifies that biosimilars require documented contraindication, intolerance, or inadequate response to preferred products before coverage of nonpreferred alternatives.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
by Apr 1, 2026 · 6 steps
01Billing team must update billing software and fee schedules to recognize and process three new HCPCS codes—M0233 (first dose), M0234 (second dose), and Q0238 (injection by mg)—for hospitalized COVID-19 patients on corticosteroids requiring supplemental oxygen or mechanical ventilation.
02Update claim submission logic to require documentation that patients meet all clinical criteria (hospitalization, systemic corticosteroid use, and respiratory support requirements).
03Configure system to route claims using M0233/M0234/Q0238 to appropriate authorization queues if prior authorization is required.
04Train billing staff on new codes and ensure providers document clinical indicators supporting medical necessity.
05Update superbill templates and encounter forms to include the new COVID-19 tocilizumab indications.
06For tocilizumab requests generally, implement workflow requiring documentation of preferred product trial (tocilizumab-aazg or tocilizumab-anoh) before approving nonpreferred alternatives; claims for nonpreferred products without documented contraindication, intolerance, or inadequate response will be denied.
Codes mentioned
J3262M0233M0234Q0238
Original notice
MA08.045p, Tocilizumab and Related Biosimilars for Intravenous Infusion and Subcutaneous Injection
medpolicy.ibx.com · Always check the source before changing claims.
Related changes
See all Independence Blue Cross changes →08.00.85s, Tocilizumab and Related Biosimilars for Intravenous InfusionMediumEffective Apr 1, 2026 · PharmacyMA08.045r, Tocilizumab and Related Biosimilars for Intravenous Infusion and Subcutaneous InjectionMediumEffective Sep 21, 2026 · PharmacyMA08.045q, Tocilizumab and Related Biosimilars for Intravenous Infusion and Subcutaneous InjectionMediumEffective Jul 1, 2026 · PharmacyMA08.045m, Tocilizumab and Related Biosimilars for Intravenous Infusion and Subcutaneous InjectionMediumEffective Jul 1, 2025 · PharmacyBrowse every Independence Blue Cross change in the policy list